Heart check for new sickle cell drug: healthy volunteers take part in safety study
NCT ID NCT07023029
First seen Oct 31, 2025 · Last updated Apr 28, 2026 · Updated 29 times
Summary
This study looked at how a new medicine called etavopivat affects the heart's electrical activity. It involved 33 healthy adults aged 18 to 55. Participants received different doses of the medicine, a placebo, or an approved heart drug to compare effects. The goal was to ensure the medicine is safe for the heart before testing it further in people with sickle cell disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PAREXEL Intl - EPCU-Baltimore
Baltimore, Maryland, 21225, United States
Conditions
Explore the condition pages connected to this study.